Effect of hyoscine -n-butylbromide on the duration of active phase of labour in term pregnancies: a randomized-controlled clinical trial.

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

PACTR

Registry ID

PACTR202502489216837

Enrollment

132

Registered

2025-02-24

Start date

2024-09-09

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

LABOUR

Interventions

PLACEBO

HYOSCINE N BUTYL BROMIDE

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Only women who give informed consent, Age of 18 years or older, Pregnant women with term pregnancy that come in spontaneous established active phase of labour, Singleton pregnancy, Vertex presentation with no contraindication to vaginal delivery.

Exclusion criteria

Exclusion criteria: Medical illness like hypertension, diabetes, pre-eclampsia. Sickle cell disease, Those with previous scar, Antepartum hemorrhages, Prior pre labour rupture of membrane.

Design outcomes

Primary

Measure	Time frame
DURATION OF ACTIVE PHASE OF FIRST STAGE OF LABOUR	—

Secondary

Measure	Time frame
DURATION OF SECOND AND THIRD STAGES OF LABOUR ;MATERNAL AND FETAL OUTCOMES VIZ-A-VIZ OPERATIVE DELIVERIES, POSTPARTUM HEMORRHAGE, MATERNAL SIDE EFFECTS, FETAL APGAR SCORES AT 1ST AND 5TH MINUTES AND NEONATAL ADMISSIONS TO INTENSIVE CARE UNIT	—

Countries

Nigeria

Contacts

Public ContactYUSUF ALFA

SENIOR REGISTRAR

alfayusuf20@gmail.com2347037483348

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026